Fraunhofer-Institut für Molekularbiologie und Angewandte Oekologie IME ScreeningPort (IME-SP)
The Fraunhofer IME ScreeningPort (IME-SP) is part of the Fraunhofer Institute for Molecular Biology and Applied Ecology IME which conducts research in the field of applied life sciences from a molecular level to entire ecosystems.
The mission of IME-SP is to bridge the gap between basic academic research and the life sciences industry in the field of drug discovery and development. With state-of-the-art infrastructure at its location in Hamburg, established processes and innovative technologies, IME-SP positioned itself as a world-leading research partner for small-molecule screening. It acts in the 4 areas:
- Drug Discovery - IME-SP provides a complete drug discovery research covering all stages from target validation via small molecule screening to candidate selection
- Biomarker and Translational Research – In our specialist laboratory facilities embedded in a University clinical research centre, we support biomarker discovery studies for clinical and pre-clinical research projects
- Enabling Technologies – The department actively develops and benchmarks novel assay and screening technologies in partnership with the life-science industry
- R&D Information Technologies – IME-SP provides expertise in life science oriented informatics areas including Computational Chemistry, Cheminformatics, Bioinformatics and scientific data preparation and analysis as well is hosting Information Hubs for industry and academic consortia.
Key staff involved
Prof. Dr. Carsten Claussen (Head of IME-SP) – is a serial founder of Life Science companies: European ScreeningPort GmbH now part of IME ScreeningPort; Evotec Technologies GmbH now PerkinElmer. His main interests are models for innovation in ”Translational Drug Discovery“, Big Data applications and new tools & technologies within Life Sciences industry. His background is robotics and automation with a degree in engineering. He holds a professorship at the Heinz Nixdorf Institute for business informatics.
Dr. Philip Gribbon (Head of Science and Operation) – responsibilities include project acquisition and delivery at IME-SP. His scientific interest covers the development of new physiologically relevant assay systems for drug discovery applications including readouts based on iPS and primary cells. He has a PhD in Biophysics from Imperial College London and has worked extensively in the Pharma industry (Pfizer and GSK) where he was responsible for HTS and Hit to Lead Studies. Philip also serves as Coordinator of EU-OPENSCREEN an ESFRI infrastructure for Chemical Biology.
Dr. Ole Pless (Senior Scientist) – is in charge of the field of Biomarker Discovery and Stem Cell research at IME SP. He holds a diploma in Biology from the University of Heidelberg and received his PhD from the Humboldt University and the Max-Delbrueck-Center for Molecular Medicine in Berlin, where he as well gained three years of postdoctoral research experience in transcription factor biology and assay development.
Oliver Keminer (Drug Discovery Scientist) – gathered 15 years of working experience in drug discovery within Eli Lilly (Lilly Forschungs GmbH, Hamburg), Evotec and European ScreeningPort. He brings in his broad know-how in assay development and validation (enzymatic and cell-based assays), target validation and compound profiling. Oliver holds a diploma in biology from the Ruhr-University of Bochum.
Dr. Mira Grättinger (Project Management, Senior Scientist) – is in charge of Project Management at Fraunhofer IME-SP, including the acquisition and administration of projects funded by public sources (BMBF, EU, IMI) and in addition delivering dissemination and exploitation activities. She previously established the assay development and screening department at a Munich biotech company before taking over responsibility for the Business Development of European ScreeningPort in 2008, which was integrated into Fraunhofer IME in 2014. Mira holds a diploma in biology and a PhD in biochemistry from the Universities of Regensburg and Hamburg.